FDA nod for first Interchangeable insulin product, Semglee

29 July 2021
viatris_large

The US Food and Drug Administration approved the first interchangeable biosimilar insulin product, Semglee (insulin glargine-yfgn), from Mylan, a company that morphed into Viatris (Nasdaq: VTRS) as a result of its merger with Pfizer’s generics and biosimilars business, Upjohn, and whose shares rose 3.3% to $14.70 on the news.

Semglee is both biosimilar to and interchangeable with Lantus (insulin glargine), which is marketed by Sanofi (Euronext: SAN), and generated first-half 2021 sales of 1.29 billion euros ($1.52 billion) for the French firm.

As an interchangeable biosimilar product, Semglee) may be substituted for Lantus at the pharmacy-level without the intervention of the prescribing health care provider, subject to state pharmacy laws.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars